DNA

Tonix Pharmaceuticals Announces Publication in Microorganisms of Technology that Expands Company’s Capabilities in Generating Potential Therapeutic Fully Human Antibodies Against SARS-CoV-2 and Other Pathogens

High-throughput, high-content imaging-based assay developed to screen convalescent sera for neutralizing antibodies to SARS-CoV-2 variants Study highlights Tonix’s internal R&D…

1 year ago

ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

ZYNLONTA® net sales of $17.0 million in 2Q 2024; Commercial profitability achieved during first half of 2024 LOTIS-7 trial enrollment…

1 year ago

Harmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028

WAKIX® (pitolisant) Net Revenue of $172.8 Million for Second Quarter 2024; ~29% Growth Year-over-Year Next Generation Pitolisant High-Dose (HD) Program…

1 year ago

Excision BioTherapeutics Awarded a “Fierce 15” Biotech Company of 2024

Company Applying its Proprietary CRISPR Technology to Address Recurrent Infections in Herpes Simplex Keratitis (HSK)HSK is the Leading Cause of…

1 year ago

Hitachi High-Tech Acquires Majority Interest in Nabsys

Transaction Strengthens the Molecular Research and Diagnostics Business by Providing Human Genome Analysis Solutions TOKYO and PROVIDENCE, R.I., Aug. 1,…

1 year ago

Wave Life Sciences Second Quarter 2024 Financial Results Scheduled for August 8, 2024

CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on…

1 year ago

Bionano Announces Presentation of Optical Genome Mapping Utility Across Cancer Research Applications at the Cancer Genomics Consortium (CGC) 2024 Annual Meeting

SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- A sponsored exhibitor session will feature Dr. Phillip Michaels from Harvard Medical…

1 year ago

CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024

SOUTH SAN FRANCISCO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field…

1 year ago

R1 RCM to be Acquired by TowerBrook and CD&R for $8.9 Billion

Stockholders to Receive $14.30 Per Share in CashMURRAY, Utah, Aug. 01, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM)…

1 year ago

Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update

End-of-treatment data presented at the EASL Congress from two Phase 2a clinical trials supports advancing imdusiran as a potential cornerstone…

1 year ago